Role and Expression of MXRA5 in Placental Connective Tissue Remodelling in Preeclampsia

Pre-Eclampsia Clinical Trial

Official title:

Role and Expression of Matrix-remodelling Associated 5 Protein (MXRA5) in Connective Tissue Remodelling of Placenta in Preeclampsia

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT04287998
• Other study ID #: MXRA5 in preeclampsia
• Status: Not yet recruiting
• Start date: April 1, 2020
• Est. completion date: May 1, 2021

Study information

• Verified date: February 2020
• Source: Assiut University
• Contact: Shimaa A Abd Elrahman, assistant lecturer
• Phone: 01069873568
• Email: shimo_ahmed_89[@]yahoo.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

1. To measure the level of expression of MXRA5 and ANXA4 genes in preeclampsia (PE).

2. To detect the effect of heavy metals (lead (Pb) and arsenic (AR)) on these two genes in the pathology of PE.

3. To explore the association of the previous two genes with the heavy metals in link with Phosphoinositide 3-kinases/Protein Kinase B (PI3K/AKT) pathway.

4. To detect Syndecan-1 by immunohistochemical antibodies.

5. To define the role of extracellular matrix remodelling in PE.

Description:

• Preeclampsia (PE) is a diverse multisystem syndrome defined as a new onset of hypertension along with evidence of significant multiorgan dysfunction in previously normotensive women 20 weeks of gestation (1)

• The incidence of PE is around 2 - 8 % of pregnancies and it causes about 50,000 deaths worldwide every year (2).

• In Egypt, it complicates 6% - 8% of pregnancies (3).

• Placentation processes include trophoblastic invasion, vascularization of trophoblast to establish and maintain feto-placental vasculature, and subsequent maternal vascular remodeling (4). Extravillous trophoblastic (EVT) cells are crucial for this process (5). If the function of extravillous trophoblast cells is deficient, it can result in PE (6).

• PI3K/AKT pathway plays important roles in placental development and fetal growth (7). PI3K/AKT signaling pathway is important for cell proliferation, migration, invasion and glycolysis/gluconeogenesis (8). AKT can further activate different downstream factors, which plays a predominant role in angiogenesis, vascular permeability and migration (9).

• Matrix metalloproteinase (MMPs) are essential proteases for trophoblast invasion and migration as they promote degrading of the extracellular matrix improving the the cell invasion, while the tissue inhibitors of matrix metalloproteinases (TIMPs) are normal tissue proteins that inhibit the action of MMPs (10).

• Annexin A4 (ANXA4) has been shown to participate in regulation of cellular growth, invasion, and apoptosis. ANXA4 has role in many forms of cancer (11). It was found that ANXA4 expression was downregulated in PE placentas compared with the normal placentas. However, the exact role of ANXA4 in the invasion and survival of trophoblast cells remains less understood.

• ANXA4 binds to the plasma membrane in a Ca2+- dependent manner and regulates its downstream signaling transduction, including phosphoinositide-3-kinase PI3K/AKT signalling (12).

• Matrix-remodelling associated 5 (MXRA5) is a member of the MXRA protein family, participating in cell adhesion and extracellular matrix remodelling (13). This protein is expressed in primates but not in rat or mouse. The function of this protein remains elusive. It resembles the vascular endothelial growth factor (VEGF) receptor and has anti-inflammatory and anti-fibrotic properties (14). Somatic mutations of MXRA5 are found in non-small cell lung cancer and in colorectal cancer (15).

• The expression of MXRA5 was shown to be downregulated in the placentae of PE patients which consequently leads to the inhibition of PI3k/AKT pathway (16).

• As regard that both of ANXA4 and MXRA5 downregulate PI3k/AKT pathway, they are associated to be linked to the pathogenesis of PE.

• Endothelial glycocalyx (EG), the most important protective structure of the endothelium, is an external layer of endothelial cells composed of different proteoglycans (PGs), glycoproteins, glycolipids, and glycosaminoglycans (GAGs). The protective role of EG for endothelium includes for example maintenance of tissue integrity, prevention of leukocytes and platelet adhesion and antithrombotic activity (17). Examples of clinical consequences of EG damage are albuminuria and edema (18).

• Syndecan-1 (SDC-1) is one of the important PGs of EG (19).

• Lead (Pb) is a widespread heavy metal pollutant. Excess Pb in the environment is usually produced via anthropogenic activities, such as mining and untreated sewage irrigation water (20).

• Arsenic (Ar) is a major toxicant in the environment, and a high level of exposure carries an increased risk of cancers and many disorders (21).

• Both of lead and arsenic have been proven to inhibit the PI3K/AKT pathway (22), (23). In this study, lead (Pb) and arsenic (Ar) will be linked to PE through inhibition of PI3K/AKT pathway.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 50
• Est. completion date: May 1, 2021
• Est. primary completion date: April 1, 2021
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Female
• Age group: 20 Years to 40 Years

Eligibility

Inclusion Criteria:

• Gestational age is >28 weeks.

• Clinically diagnosed PE with blood pressure (=140/90 mmHg) and proteinuria (=300mg/dl).

• Healthy pregnant women (age matched control group).

Exclusion Criteria:

• Gestational diabetes.

• Pregestational hypertension (essential hypertension) or proteinuria.

• Systemic illness.

• Vaginal infection.

• Major known fetal or chromosomal anomalies.

• Multiple gestations.

• Intrauterine infections.

• Preterm premature rupture of membranes.

• Sepsis.

• Fever.

• Colitis ulcerosa.

• Crohn's disease.

• Chronic renal disease.

• Rheumatic disease.

Related Conditions & MeSH terms

• Eclampsia
• Pre-Eclampsia

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Assiut University

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Gene expression level of MXRA5 gene in PE patients and control group		1 year
Secondary	Gene expression level of ANXA4 in PE patients and control group.		1 year
Secondary	Gene expression level of TIMP1 gene in PE patients and control group.		1 year
Secondary	Protein level measurement of phosphorylated AKT(pAKT) in PE patients and control group.		1 year
Secondary	Measurement of lead and arsenic level in PE patients and control group.		1 year